Levetiracetam Ametas (Levetiracetam)

• Levetiracetam is an antiepileptic drug that reduces neuronal excitability in various seizure types.
• Partial seizures: decreases frequency and severity of focal seizure episodes, improving daily functioning and reducing the need for rescue medication in patients with epilepsy.
• Generalized tonic‑clonic seizures: helps prevent the occurrence of convulsive seizures that involve both cerebral hemispheres, thereby lowering the risk of injury and status epilepticus.
• Myoclonic seizures: reduces sudden, brief muscle jerks characteristic of myoclonic epilepsy, contributing to better motor control and quality of life.

• Levetiracetam binds to the synaptic vesicle protein SV2A, modulating neurotransmitter release and stabilizing neuronal membranes. This interaction reduces excessive calcium influx and dampens hyper‑synchronous neuronal firing, thereby decreasing seizure propagation and overall neuronal excitability in the central nervous system. The precise downstream pathways remain incompletely understood, but the net effect is a reduction in the likelihood of abnormal electrical discharges that underlie epileptic seizures.

Levetiracetam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Fatigue: feeling unusually tired or lacking energy.
• Headache: mild to moderate cranial pain.
• Somnolence: increased sleepiness or difficulty staying awake.
• Nausea: upset stomach or feeling of vomiting.
• Irritability: increased agitation or emotional instability.

Serious or Rare Side Effects

• Severe allergic reaction: rash, swelling, or difficulty breathing.
• Mood changes: depression, anxiety, or suicidal thoughts.
• Skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Multi‑organ involvement: rare cases of hepatitis or blood dyscrasias.
• Rash with blistering: rare dermatologic reaction requiring immediate medical attention.
• Blood disorders: rare thrombocytopenia or leukopenia.

• When prescribing levetiracetam, clinicians should consider several precautionary measures to ensure safe use.
• Renal impairment: assess kidney function and adjust dose if necessary.
• Hepatic impairment: monitor liver enzymes and use with caution.
• Psychiatric history: observe for mood alterations or suicidal ideation.
• Concomitant alcohol: advise patients to limit alcohol consumption.
• Pregnancy: discuss potential risks and benefits with the prescribing physician.
• Store at room temperature: keep in the original container, protect from moisture and light.

Levetiracetam can interact with other medicines, influencing its effectiveness or safety.

Major Interactions (Avoid)

• Phenobarbital: may significantly reduce levetiracetam plasma concentrations.
• Carbamazepine: can decrease levetiracetam efficacy through enzyme induction.
• Phenytoin: may lower levetiracetam levels, compromising seizure control.

Moderate Interactions (Monitor Closely)

• Valproic acid: may increase levetiracetam concentrations, requiring monitoring.
• Topiramate: additive central nervous system depression may enhance sedation.
• Alcohol: can potentiate dizziness and somnolence.